Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changhoon Yoo

Showing results (151-160 of 250) with videos related to

Pageof 25
Sort By:
Cancer Research and Treatment|May 4, 2023
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration DetectionDong-Hoon Lim, Hyunseok Yoon, Kyu-Pyo Kim, et al.
Journal of Hepatology|October 2, 2025
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumabHyung-Don Kim, Sun Jin Sym, Hong Jae Chon, et al.
Journal of Cancer Research and Clinical Oncology|March 21, 2021
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysisAndrea Casadei-Gardini, Lorenza Rimassa, Margherita Rimini, et al.
Oncology|March 23, 2025
Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular CarcinomaHyung-Don Kim, Young-Gyu Park, Hyeyeon Hong, et al.
Cancer Research and Treatment|July 12, 2019
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaKyoungmin Lee, Kyunghye Bang, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|April 18, 2023
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trialHyehyun Jeong, Kyu-Pyo Kim, Jae Ho Jeong, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2024
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa studyHyehyun Jeong, Bum Jun Kim, Choong-Kun Lee, et al.
Cancer Research and Treatment|January 16, 2018
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract CancerChanghoon Yoo, Boram Han, Hyeong Su Kim, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
Pageof 25

Showing results (151-160 of 250) with videos related to

Sort By:
Pageof 25
Cancer Research and Treatment|May 4, 2023
Analysis of Plasma Circulating Tumor DNA in Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Modified FOLFIRINOX: Clinical Relevance of DNA Damage Repair Gene Alteration DetectionDong-Hoon Lim, Hyunseok Yoon, Kyu-Pyo Kim, et al.
Journal of Hepatology|October 2, 2025
Multicenter phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumabHyung-Don Kim, Sun Jin Sym, Hong Jae Chon, et al.
Journal of Cancer Research and Clinical Oncology|March 21, 2021
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysisAndrea Casadei-Gardini, Lorenza Rimassa, Margherita Rimini, et al.
Oncology|March 23, 2025
Atezolizumab plus Bevacizumab Is Associated with Favorable Overall Survival over Lenvatinib in Patients with Unresectable Hepatocellular CarcinomaHyung-Don Kim, Young-Gyu Park, Hyeyeon Hong, et al.
Cancer Research and Treatment|July 12, 2019
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic AdenocarcinomaKyoungmin Lee, Kyunghye Bang, Changhoon Yoo, et al.
Hepatology (Baltimore, Md.)|April 18, 2023
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trialHyehyun Jeong, Kyu-Pyo Kim, Jae Ho Jeong, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2024
Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa studyHyehyun Jeong, Bum Jun Kim, Choong-Kun Lee, et al.
Cancer Research and Treatment|January 16, 2018
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract CancerChanghoon Yoo, Boram Han, Hyeong Su Kim, et al.
Oncotarget|April 27, 2017
Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinomaChanghoon Yoo, Jihoon Kang, Deokhoon Kim, et al.
Targeted Oncology|September 7, 2021
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional ExperienceMargherita Rimini, Changhoon Yoo, Sara Lonardi, et al.
Pageof 25